

## Disclosures

### Personal Commercial (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Astra Zeneca	Research/Research Grants ‡ Ticagrelor in Coronary Microvascular Dysfunction	Significant (>= \$5,000)	General Cardiology
Bayer Healthcare Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
Menarini	Consultant Fees/Honoraria	Modest (< \$5,000)	Stable Ischemic Heart Disease
Terumo	Research/Research Grants ‡ PAMICO	Significant (>= \$5,000)	Acute Coronary Syndromes

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
The Hospital research Foundation Group	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
The University of Adelaide ‡ National Health and Medical Research Council	Research/Research Grants ‡ PAMICO	Significant (>= \$5,000)	Vascular Medicine
University of Adelaide ‡ Commercial Accelerator Scheme	Research/Research Grants ‡ The anti-anginal benefits of Zibotentan in the coronary Slow Flow Phenomenon.	Significant (>= \$5,000)	Stable Ischemic Heart Disease

### Clinical Trial Enroller (2)

Trial Name	Trial Sponsor	Trial Funding Source
PREVAIL	New Amsterdam	
VICTORION-2	Novartis Corporation	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 9/28/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 9/28/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 9/28/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 9/28/2023

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.